Senseonics (NYSE:SENS) Now Covered by StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Senseonics (NYSE:SENS) in a research note issued to investors on Sunday. The firm set a “sell” rating on the stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $2.00 price target on shares of Senseonics in a research note on Friday, November 15th.

Senseonics Trading Down 2.1 %

Senseonics stock opened at $0.32 on Friday. Senseonics has a 1 year low of $0.28 and a 1 year high of $0.75. The firm’s 50 day moving average price is $0.34 and its 200-day moving average price is $0.39. The company has a debt-to-equity ratio of 59.17, a current ratio of 2.47 and a quick ratio of 2.38. The stock has a market cap of $188.12 million, a P/E ratio of -2.43 and a beta of 0.79.

Hedge Funds Weigh In On Senseonics

Several institutional investors have recently added to or reduced their stakes in SENS. Vanguard Group Inc. boosted its position in shares of Senseonics by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 22,525,039 shares of the company’s stock valued at $11,963,000 after acquiring an additional 155,715 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Senseonics by 3.2% in the 3rd quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company’s stock worth $2,042,000 after buying an additional 179,103 shares during the last quarter. Symmetry Partners LLC purchased a new stake in shares of Senseonics during the 3rd quarter valued at about $164,000. Cubist Systematic Strategies LLC lifted its holdings in shares of Senseonics by 25.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock valued at $166,000 after acquiring an additional 85,501 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in Senseonics by 16.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock worth $196,000 after acquiring an additional 51,000 shares in the last quarter. Hedge funds and other institutional investors own 12.36% of the company’s stock.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.